Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

Pediatric research - 1 Jan 2005

Kenerson Heidi, Dundon Trevor A, Yeung Raymond S

Abstract excerpt

Tuberous sclerosis complex (TSC) presents in the pediatric population with a constellation of benign tumors that affect the brain, heart, kidney, lung, and skin. No therapy has been shown to halt disease progression or to prevent its onset. The pathogenesis of TSC stems from the inactivation of one of the two TSC genes, TSC1 and TSC2. A key function of these genes is to regulate the mammalian target of rapamycin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunoblotting
Share to Immunosuppressive Agents
Share to Pituitary Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinases

Share to Ribosomal Protein S6 Kinases

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Share to Tuberous Sclerosis

Source

Identifiers

PMID: 15557109
DOI: 10.1203/01.PDR.0000147727.78571.07

Genes

TSC1
TSC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.PMID 15557109Read ↗

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disordersSemantic proximity Read ↗

The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition.Semantic proximity Read ↗

Mammalian target of rapamycin: master regulator of cell growth in the nervous system.Semantic proximity Read ↗

Mourning Dr. Alfred G. Knudson: the two‐hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complexSemantic proximity Read ↗

Paradigm shift in the treatment of tuberous sclerosis: Effectiveness of everolimusSemantic proximity Read ↗

Rapamycin extends maximal lifespan in cancer-prone mice.Semantic proximity Read ↗

Revisiting Brain Tuberous Sclerosis Complex in Rat and Human: Shared Molecular and Cellular Pathology Leads to Distinct Neurophysiological and Behavioral Phenotypes.Semantic proximity Read ↗

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.Semantic proximity Read ↗

Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.Semantic proximity Read ↗

Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches.Semantic proximity Read ↗

Comprehensive Evaluation of Rapamycin’s Specificity as an mTOR InhibitorSemantic proximity Read ↗

ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.